Business
Novavax Grows Presence at World Vaccine Congress and 32nd European Congress of Clinical Microbiology & Infectious Diseases
New data on COVID-19 Influenza combination vaccine and seasonal influenza vaccine to be presented at World Vaccine CongressSeveral abstracts and presentations
About this update from Novavax, Inc.
[{"type":"text","content":"New data on COVID-19 Influenza combination vaccine and seasonal influenza vaccine to be presented at World Vaccine CongressSeveral abstracts and presentations slated to highlight updates on NVX-CoV2373, Novavax' COVID-19 vaccineGAITHERSBURG, Md., April 18, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, will provide a first look at data from its COVID-19 influenza combination vaccine and seasonal influenza vaccine trials, at the World Vaccine Congress (WVC) in Washington, DC, April 18 - 21, 2022. In addition, the latest data on its protein-based COVID-19 vaccine candidate, NVX-CoV2373, will be presented at both WVC and the 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in in Lisbon, Portugal, April 23 - 26, 2022. Data from eight abstracts and presentations, including four oral presentations, will be presented across the two congresses.\nGregory M. Glenn, M.D., President, Research and Development, Novavax, said: \"Our presence at these two leading industry conferences shows our ongoing commitment to addressing COVID-19, and the advances we have made towards a next-generation influenza vaccine. We look forward to sharing these updates that further demonstrate the potential for our platform.\"\nKey Novavax presentations during WVC:\nGlenn, G\nHow long will our immunity against COVID-19 last for and will our vaccines continue to work against VoCs?\nPanel\nApril 19, 2022\n8:45 – 9:45 ET\nKim, D\nMonitoring COVID-19 Vaccine Safety under Emergency Use Authorization: Challenges and Lessons?\nPanel\nApril 20, 2022\n12:10 – 1:10 ET\nGlenn, G\nClinical Update on Novavax's Recombinant Nanoparticle Protein Subunit COVID-19 Vaccine as a Booster\nOral\nSession COVID & Beyond – M4\nApril 20, 2022\n12:40 – 12:00 ET\nShinde, V\nUpdate on Novavax' NanoFlu* vaccine and COVID-19-Influenza Combination Vaccine development\nOral\nSession Influenza and Respiratory – M4\nApril 20, 2022\n12:40 – 1:10 ET\n*NanoFlu identifies a recombinant hemagglutinin (HA) protein nanoparticle influenza vaccine candidate produced by Novavax. This investigational candidate was evaluated during a controlled phase 3 trial conducted during the 2019-2020 influenza season.\nKey Novavax presentations during ECCMID:\nToba...